Wexford, PA, (August 5, 2015) InteloMed, Inc., an emerging leader and developer of non-invasive cardiovascular monitoring technology, today announced the appointment of Jill F. Schiaparelli as President and Chief Executive Officer and an Executive Member of the Company’s Board of Directors. The new appointment was made based on the Company’s forward-thinking commercialization, distribution, strategic partnering and OEM plans for their next-generation non-invasive cardiovascular monitoring platform.
“We are thrilled that Jill has joined InteloMed as President and CEO,” stated Mark Rossi, Chairman of the Board for InteloMed. “Jill’s strong track record of commercial success with innovative medical technologies will be instrumental in advancing the Company’s growth plans.”
Ms. Schiaparelli joins InteloMed after serving as Chief Marketing Officer / Corporate Officer for AxoGen, Inc. (NASDAQ: AXGN) where she helped to develop and execute the company’s commercial strategy and conduct several rounds of financing. This resulted in 9 consecutive quarters of double-digit revenue growth and an uplist to the NASDAQ exchange. Prior to Axogen, she was the Global Vice President of Commercial Strategy and Business Development at ApaTech, a UK-based bone regeneration company which was successfully acquired by Baxter Healthcare in 2010.
Prior to entering the startup company realm, Ms. Schiaparelli held senior leadership positions at Johnson & Johnson including positions at their Ethicon, Inc. and Ethicon Endo Surgery divisions. Earlier in her career, she was a Vice President in the investment banking arena.
Ms. Schiaparelli joined Intelomed’s Board as an Independent Director earlier in 2015.
“Intelomed’s CVInsight™ Platform is extremely impressive and its potential to redefine the current standards for non-invasive monitoring of cardiovascular stress is incredible,” commented Ms. Schiaparelli. “I know first-hand the impact of a cardiovascular event in my own family – I am excited to be a part of a company that will make a significant difference in the lives of many people.”
Intelomed is redefining the standard of care in intelligent cardiovascular monitoring in hospitals and health care facilities through its non-invasive CVInsight™ Platform. The CVInsight™ Platform provides real-time insights on the stress level of the cardiovascular system to inform clinical decisions which, as part of a well-managed care plan, may lead to earlier detection of cardiovascular decline, earlier intervention, decreased hospitalization and improved patient outcomes.
The CVInsight™ Platform has functionality in hospital and outpatient settings and has clinical applications in multiple areas including hemodialysis, heart failure, and the surgical continuum.
InteloMed is headquartered in Wexford, PA.
For more information, visit us at www.InteloMed.com.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.
PR / Media Contact: